Catalent, novo nordisk and european commission
Catalent gains on reports it's likely to be granted EU approval for Novo Holdings deal (update)
The European Commission is expected to give unconditional approval for the $16.5 billion purchase of Catalent (NYSE: CTLT) as the parties haven't been asked to attend a "state of play" meeting, according to an MLex report that circulated on Friday.
Swiss biotech Alentis Therapeutics has secured $181.4 million, money that will be used to launch clinical trials for two ...
As sales of Novo Nordisk’s GLP-1 drugs for diabetes and obesity continue to soar, the Danish drugmaker is once again ...
European Union antitrust officials are asking rival pharmaceuticals firms for their input on Novo Holdings planned $16.5 ...
At that time, T. Rowe Price was the bigger shareholder, with a 10.1% stake, followed by Novo Holdings—the controlling ...
This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...
EU antitrust regulators are set to clear without conditions Novo Holdings' planned $16.5 billion takeover of Catalent, a ...
BRUSSELS/LONDON, Nov 22 (Reuters) - Novo Holdings is set to gain unconditional EU antitrust approval for its planned $16.5 billion takeover of U.S. contract drug maker Catalent (CTLT.N), opens new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback